Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists)

Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update

“…Such low utilization of PCSK9 inhibitors was also reported by Chamberlain et al., who found <1% of patients with dyslipidemia or coronary heart disease were prescribed PCSK9 inhibitors [15] . One important barrier for physicians to prescribe PCSK9 inhibitors is the complex and time-consuming pre-authorization process [16] . Clinical inertia may also explain in part the failure to timely treatment of PCSK9 inhibitors [17] .…”

Applying implementation science to improve care for familial hypercholesterolemia

“…A recent study found 30% of young patients with FH had poor adherence to lipid-lowering therapies, the main reason being lack of motivation. A survey of primary care physicians and cardiologists found several factors influencing prescribing of PCSK9 inhibitors: clinical type (cardiologist more likely to order) and practice setting and location (urban and academic centers more likely to order) [17].…”